Med. Pro Praxi 2007; 4: 156-160 [Interní Med. 2007; 9(1): 7-10]

Probiotika v gastroenterologii a hepatologii

MUDr. Jana Juránková1, prof. MUDr. Jan Lata CSc2, MUDr. Veronika Příbramská2, MUDr. Tomáš Ostřížek3
1 Oddělení klinické mikrobiologie, Fakultní nemocnice Brno, pracoviště Bohunice
2 Interní gastroenterologická klinika, FN Brno
3 Centrum kardiovaskulární a transplantační chirurgie v Brně

V článku je uveden přehled indikací k podání probiotik v oblasti gastroenterologie a hepatologie. Probiotika jsou již nyní důležitou součástí léčby idiopatických střevních zánětů a průjmů. V řadě dalších diskutovaných oblastí byl jejich prospěšný vliv popsán a do budoucna lze předpokládat rozšíření indikací probiotik i u dalších diagnóz.

Keywords: probiotika, gastroenterologie, hepatologie

Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Juránková J, Lata J, Příbramská V, Ostřížek T. Probiotika v gastroenterologii a hepatologii. Med. praxi. 2007;4(4):156-160.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Allen SJ. Probiotics for threating infectious diarrhoea (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Go to original source...
    2. Baron TH, Morgan E. Acute necrotizing pancreatitis.N Engl J Med 1999; 340: 1412-1417. Go to original source... Go to PubMed...
    3. Besselink MCH, Timmerman HM, Buskens E, et al. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA) Design and rationale of double-blind, randomized, placebo-controlled multicentric study. BMC Surgery 2004; 4: 12-18. Go to original source... Go to PubMed...
    4. Black FT. Prophylactic effcacy of lactobacilli on travelers´s diarrhoea. In: Steffens R edit Travel Medicine. Proceedings of the First Conference on International Travel Medicine 1988. Berlin: Springler-Verlag 1989.
    5. Boča M, Vyskočil M, Mikulecký M, et al. Komplexná liečba chronickej hepatálnej encefalopatie doplnená probiotikom Čas Lék Čes 2004; 143: 324-328.
    6. Brůha R, Mareček Z, Petrtýl J, Kaláb M. Jaterní encefalopatie - komplikace jaterní cirhózy. Praha, Medprint, 2000.
    7. Cahn DR. Über die nach Gram färbbaren Bacillen des Säulingsstuhles (Bacilli of infant stools stainable according to Gram.) Centralblatt für Bakteriologie I. Abteilung Originale 1901; 30: 721-726.
    8. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744-2749. Go to original source... Go to PubMed...
    9. Cremonini F, Di Caro S, Nista EC, et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16: 1461-1467. Go to original source... Go to PubMed...
    10. D´Souza AL, Rajkumar CR, Cooke J, Bulpitt Cj. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324: 1361-1364. Go to original source... Go to PubMed...
    11. Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Pancreas 1996; 13: 198-201. Go to PubMed...
    12. Döderlein A. Das Scheidensekret und seine Bedeutung für das Puerperalfieber. (The vaginal transsudate and its significance for childbed fever.) Centralblatt für Bacteriologie 1892; 11: 699-700.
    13. Fedorak RN, Madsen KL. Probiotics and prebiotics in gastrointestinal disorders. Curr Opin Gastroentrol, 2004; 20: 146-155. Go to original source... Go to PubMed...
    14. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003; 15: 313-315. Go to original source...
    15. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989; 66: 365-378. Go to original source... Go to PubMed...
    16. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209. Go to original source... Go to PubMed...
    17. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis Eur J Gastroenterol Hepatol. 2003; 15 (6): 697-698. Go to original source... Go to PubMed...
    18. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-1464. Go to original source... Go to PubMed...
    19. Havenaar R, Ten Brink B, Huis in't Veld JHJ. Selection of strains for probiotic use. In: Fuller R, ed. Probiotics: the scientific basis. London: Chapman and Hall, 1992: 209-224. Go to original source...
    20. Isenmann R, Runzi M, Kron M, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: A placebo-controlled, double-blind trial. Gastroenterology 2004; 126: 997-1004. Go to original source... Go to PubMed...
    21. Kim HJ, et al. A randomized controlled trial of probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895-904. Go to original source... Go to PubMed...
    22. Kruis W, Frič P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine Gut 2004; 53: 1617-1623. Go to original source... Go to PubMed...
    23. Lata J, Juránková J, Příbramská V, et al. Vliv podání Escherichia coli Nissle (Mutaflor) na střevní osídlení, endotoxemii, funkční stav jater a minimální jaterní encefalopatii u nemocných s jaterní cirhózou. Vnitř. Lék 2006; 52 (3): 215-220.
    24. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology, 2003; 37: 344-349. Go to original source... Go to PubMed...
    25. Lilly DM, Stillwell RH. Probiotics: growth promoting factors produced by microorganisms. Science 1965; 147: 747-748. Go to original source... Go to PubMed...
    26. Liu Q, Duan ZP, Ha D, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis- Hepatology 2004; 39: 1441-1449. Go to original source... Go to PubMed...
    27. Lodinová-Žádníková R, Cukrowská B. Influence of oral colonization with a non-enteropathogenic E.coli strain after birth on the frequency of infections and allergic diseases after 10 and 20 year. Immunology letters 1999; 69: abstr 12. 6.
    28. Lodinová-Žádníková R, Sonnenborn U. Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate 1997; 71: 224-232. Go to original source... Go to PubMed...
    29. Loguercio C, Federico A, Tuccillo C et al. Beneficial effects of probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39 (6): 540-543. Go to original source... Go to PubMed...
    30. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25: 653-658. Go to original source... Go to PubMed...
    31. Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R. Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis Diabetes Care 2004; 27: 2057-2066. Go to original source... Go to PubMed...
    32. Metchnikoff E. Prolongation of life- Optimistic Studies. New York: Putnam and sons 1908.
    33. Midolo PD, Lambert JR, Hull R, et al. In vitro inhibition of Helicobacter pylori NCTC 11637 by oganic acids and lactic acid bacteria. J Appl Bacteriol 1995; 79: 475-479. Go to original source... Go to PubMed...
    34. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114. Go to original source... Go to PubMed...
    35. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-1147. Go to original source... Go to PubMed...
    36. Nissle A. Uber die Bedeutung bakteriologischer Stuhluntersuchungen bei nichtinfektiosen Darmkrankheiten Arch Hyg Bakt 1930; 103: 124-131.
    37. O´Sullivan, MA, O´Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo controlled crossover study. Digest Liver Dis 2000; 32: 294-301. Go to original source... Go to PubMed...
    38. Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of travellers´diarrhoea by Lactobacillus GG. Ann Med 1990; 22: 53-56. Go to original source... Go to PubMed...
    39. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409. Go to original source... Go to PubMed...
    40. Rahman SH, Catton JA, McMahon MJ. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis Br J Surg 2002; 89: 1103-1107. Go to original source... Go to PubMed...
    41. Saaggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38 (suppl 2): S 104-106. Go to original source... Go to PubMed...
    42. Sheu BS, Cheng HC, Kao AW, et al. Pretreatment with Lactobacillus- and Bifidobacteriumcontaining yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy Am J Clin Nutr 2006; 83: 864-869. Go to original source... Go to PubMed...
    43. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with - containing yogurt on triple therapy for Helicobacter pylori erradicaion Aliment Pharmacol Ther 2002; 16: 1669-1675. Go to original source... Go to PubMed...
    44. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004; 4: 5-9. Go to original source... Go to PubMed...
    45. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. Journal of Pediatrics 2001; 138: 361-365. Go to original source... Go to PubMed...
    46. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001a; 33 (Suppl 2): S17-S25. Go to original source... Go to PubMed...
    47. Van Niel CW Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in childern: a metaanalysis. Pediatrics 2002; 109: 678-684. Go to original source... Go to PubMed...
    48. Venturi A, Gionchetti, P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13 (8), 1103-1108. Go to original source... Go to PubMed...
    49. Wu CD, Li MZ, Chen CL, et al. Endotoxin-induced liver injury and plasma tumor necrosis factor alfa, interleukin 6 level changes in rabbits. Chin J Dig 1995; 15: 256-258.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.